Screening and discovery refers to the early pharmacodynamic, pharmacokinetic and safety evaluation studies of a lead compound in the early discovery stage of drug development to preliminarily evaluate the potential of the compound to be a drug. During the process of drug research and development, the screening of active compounds can increase the success rates and cut costs by helping pharmaceutical companies select candidate compounds with good druggability for further development at lower costs and within the shortest time or terminate the subsequent research and development of compounds with poor druggability at an early stage.

InnoStar has established platforms for early in vitro and in vivo pharmacodynamics as well as early pharmacokinetics (including in vitro ADME assays and rapid in vivo pharmacokinetic screening) and provides multiple rapid early toxicity prediction and screening models including genotoxicity prediction models, high-throughput genotoxicity evaluation and screening models, in vitro cardiac toxicity evaluation and screening models, in vitro carcinogenicity evaluation models, high-throughput reproductive and developmental toxicity evaluation and screening models, etc. A battery of these studies provides effective and reliable data to support the optimization and druggability of candidate compounds, accelerates drug research and development and improves efficiency.

Our Advantages